Skip to content

Author

T. Hashimoto

We have 2 of 72 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Molecular residual disease: Charting a new path for treating resectable solid tumors.

Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenge...

S. Kobayashi, T. Hashimoto, H. Bando et al. · 0 citations
Review Open access Jul 2026

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC

It is proposed that the next phase of precision oncology should integrate the cellular dimension of metastasis through systematic circulating tumor cell (CTC) profiling and highlights adherent-to-suspension transition (AST) as one representative, experimentally tractable plasticity program that enables tumor cells to s...

T. Hashimoto, T. Shibuki, T. Fujisawa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.